IRW-PRESS: Medigene AG: Medigene AG sets up KRAS G12V as the first target for TCR-managed T-Zell Engager customers


Planegg/Martinsried (IRW-Pers / 09.12.2024)


The Medigene AG (Medigene oder das “Unternehmen”, FWB: MDG1, Prime Standard) is an immunological platform focused on the treatment and treatment of T-Zell-Rezeptor (TCR)-gesteuerten immunotherapies for the treatment of Krebs spezialisiert, gab heute die Auswahl der G12V mutation of KRAS (Kirsten rat sarcoma viral oncogene homolog) in the connection with HLA*A11 as the first syndrome for the common Entwicklung of T-Zell-Rezeptor-gesteuerten T-Zell-Engagern (TCR-TCEs) with WuXi Biologics.


The existing objectives are a separate Schritt in the Partnership of Medigene and WuXi Biologics, which in the next three years the Entwicklung more TCR-TCE-Konstrukte for Ziel hat. The medical expertise in the generation and characterization of highly sensitive, specified and safe (3S) TCRs with WuXi Biologics’ unique anti-CD3 monoclonal antibody (mAb), the TCE platform and the bispecific reinforcement platform Antikörperplattform WuXiBody sister.


“The rapid analysis of KRAS G12V as Target for the first program, can be used as MDG3010 in the Pipeline of the Medigene, mark the analysis of a TCR-TCE library for the therapy of treatable tumors. It is possible to see the programs reflected to effectively leverage teams more broadly in the future,” said Selwyn Ho, CEO of Medigene. “With the combination of Medigene’s 3S TCRs with the CD3 mAb and WuXi Biologics’ bispecific platform, there is a first-class therapeutic treatment in the development of the development form, the price of a large Zahl of patient addresses, which validates this, häufig auftretende KRAS-Mutation aufweisen.”


KRAS mutations are increasingly common and play a role in indications, which can affect many patients, such as B. Bauchspeicheldrüsen-, Dünndarm-, Dickdarm- and Lungenkrebs.1 In Bauchspeicheldrüsenkrebs, KRAS mutations are performed with the frühesten and critical genetic genes, which stand out in more than 95% of cases, where G12D and G12V die high rates (~65 %).2,3 In the war of 2020, building aids are the most important resources for the welfare of the world, as well as for men and women, so that new patients (496,000) may be diagnosed quickly Todesfällen (466,000) in dieser Indikation.4


The bispezoidal therapy market represents a great opportunity in the credit camp, which is the address of the uncovered treatment that is solid when it comes to haematological tumors. More than 5 million credit patients have had a small chance of survival, the urgent decay was an innovative treatment verdeutlicht. Bispecific TCR-TCEs, the immune system has a strong effect, a Krebszellen präziser is assessed from 2023 to 2030 with a duration of 40.9% Wachsen. Until 2030 the market will have a volume of über 80 billion. USD5 erreichen, was a potential broader mirror, the lending to healthcare and the care for the patients who started working.


— End of the press conference —


Uber Medigene AG


Medigene AG (FWB: MDG1) is an immunological platform focused on the Entwicklung of T-Zell-Rezeptor (TCR) treatment with effective treatment by Krebs. The end-to-end platform generates optimal 3S (sensitive, specific and sure) T-Zell receptors with unique and uncontrolled properties, which work in various therapeutic forms with TCR-stimulated T-Zell-Engager (TCR-TCE)- therapy (MDG3010), TCR-Therapien with natural Killerzellen and T-Zell-Rezeptor-modified T-Zell (TCR-T)-Therapien (MDG1015) were initiated. For more information, please visit http://www.medigene.de.


Über TCR-gesteuerte T-Zell-Engager


TCR-driven T-Zell Engager (TCR-TCEs) has developed an innovative system of “off-the-shelf” immunotherapy that will never again allow patients to produce individual products that are so easy to develop. If you have specific ownership of TCRs, you can recognize and borrow credits. Unlike conventional anti-microbial TCRs that recognize intracellularly as an extracellular soul molecule, the Peptid-Human Leukozyte-Antigenic (HLA) Complexes were presented at Krebszellen, an extensive spectrum and a frightening soul molecules were presented.


The Rahmen Zenner end-to-end platform offers a Medigene natural TCR series with higher specification, sensitivity and Security (3S). These optimal 3S TCRs can be combined with a Cluster of Differentiation 3 (CD3) T-Zell-active anti-körper combination.


The TCR-TCEs borrow the clinical pictures of patient soul on the Krebszellen, reimburse with the 3S-TCR-Teil a Soul Molecule (Krebs-Testis-Antigen or Neoantigen) that quickly comes out of the tumor. If the T-Zellen were brought into the future of the Krebszellen, they became active through the Anti-CD3 monoclonalem Antikörper (mAb), the Freisetzung of Zytokinen and zytotoxic Moleculen führt, the Nights of the Krebszellen were illuminated.


The treatment’s high-quality “Off-the-Shelf” TCR-TCEs that have the potential are also very good treatments with adoptive zell therapies.


View Medigene’s MDG3010 program


MDG3010 is the first TCR-TCE therapy program in Medigene’s pipeline. It specializes in the neoantigen KRAS (Kirsten rat sarcoma viral oncogene homolog) G12V targeting and uses from the TCR candidates from Medigenes KRAS-Targeting-TCR Library. KRAS G12V is one of the most common genes in Krebs, which has resulted in a more aggressive malady and a poor prognosis, especially in Rückfällen.


MDG3010 has an optimal TCR, the upgraded signaling device for Spezifität, Sensitivität and Sicherheit ausgewählt wurde (3S) and on KRAS G12V abzielt. There is a combination of the uniform and valid anti-CD3 monoclonal antikörper (mAb) from WuXi Biologics, a study of the Tumorzellen ermöglicht and the gleichzeitig a erschöpfung of the T-Zellen prevention.


Über KRAS


KRAS (Kirsten rat sarcoma viral oncogene homologue) is secreted by the small group of Guanosin-5-Triphosphat (GTP)-binding proteins, which are used as RAS-related GTPases. A physiological clause ensures that KRAS prevents proliferation and overcrowding.


In lending, the KRAS is highly divided, and dies with a Vielzahl of often very solid lending with the duktals Adenokarzinom of the Bauchspeicheldrüse, the nicht-kleinzelzellige longkredieten and the colorectals Karzinom. Mutations in de KRAS-generer führen zur Bildung von Neoantigenen, de uncontrolled Wachstum von Krebszellen fördern. These mutations within the KRAS genes were now in Krebszellen and ineligible, KRAS was an attractive Angriffspunkt for the TCR-stimulated therapeutic power. These things can happen a number of times, a number of mutations will occur and the recurrence of the solid tumors will increase. In CAR-T-Zellen, which is for the Recognition of Oberflächenantigene benötigen and possible nur zugänglich sind, TCRs recognize a knitteres Spektrum and Souls, einschließlich intrazellulärer Protein with KRAS Neoantigen. The tenets of this research are TCR-stimulated therapy that goes beyond the treatment of KRAS mutations and other challenging neoantigens.


This Mitteilung is best in the Zukunft-oriented Aussagen. These mirror the Meinung von Medigene zum Datum dieser Mitteilung more broadly. The Medigene tatsächlicherzielten Ergebnisse können von de zkunftsbezogeneen Aussagen erheblich abweichen. Medigene is not obliged to update the relevant information. Medigene® is a brand of Medigene AG. These markers can increase their ownership or ownership of the states.


Aus Gründen der lighter lesbarkeit will have a geschlechterspezifische different representation. Make sure you are in the sin of treatment for both Geschlechter.


Medigene AG


Pamela Kek


Tel.: +49 89 2000 3333 01


Email: investor@medigene.com


If you can no longer find the information about the Medigene information, you can send an email to an email resource (investor@medigene.com). investor@medigene.comWir were then displayed by an unanswered list of advertisements.


1 Pereira et al., Cells 2022 February; 11(3): 398.


2 Hamarsheh, S.; Gross, O.; Brummer, T.; Zeiser, R. Immunomodulatory effects of oncogenic KRAS in cancer. Wet. Common. 11, 5439 2020.


3 Stephen AG, Esposito D, Bagni RK, McCormick F. Drag Ras back into the ring. Cancer cell. 2014 Mar 17;25(3):272-81. doi: 10.1016/j.ccr.2014.02.017. PMID: 24651010.


4 Sung et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209-249.


5 https://www.kbvresearch.com/bispecific-antibodies-market/


(End)


Other:-


Medigene AG


Lochhamer Straße 11


82152 Planegg/Martinsried


Germany-


Consulting partner: -Medigene PR/IR


Tel.: -+49 89 2000 3333 01


Email: -investor@medigene.com


Website: -www.medigene.de


ISIN(s): -DE000A40ESG2 (Promotion)


Börse(n): -Regulierter Markt in Frankfurt; Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate


https://www.irw-press.at/prcom/images/messages/2024/77737/12-09-24Planegg.001.png


SUBSCRIBE TO NEWSLETTER:


Aktuelle Pressemeldungen die Unternehmens direkt in Ihr Postfach:


http://www.irw-press.com/alert_subscription.php?lang=de&isin=DE000A40ESG2


Mitteilung übermittelt by IRW-Press.com. The justifiable effect is for inhalation.


Kostenloser Abdruck mit Quellenangabe erlaubt.



Sitemap of bdtexfaivm.fns1.online

Cannabis News RSS Feeds: Weedrss.com

1000+ unique media and news posts every 24 hours…

Published 2 hours ago
Published 7 hours ago
Published 13 hours ago
Published 16 hours ago
Published 17 hours ago
Published 17 hours ago
Published 20 hours ago
Published 21 hours ago
Published 21 hours ago
Published 21 hours ago
Published 22 hours ago